Skip to main content
    K

    Kalvista Pharmaceuticals Inc (KALV)

    Official site

    BIOTECHNOLOGY

    $27.00
    +0.00 (+0.00%)

    Last updated: Jun 12, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(20/37)
    Avg Surprise
    +3.21%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.29
    Range$-0.43 - $-0.02
    6 analysts
    EPS RevisionsNo revisions (7d)
    4
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.38+24.3%
    60d ago$-0.30+3.4%
    30d ago$-0.26-10.3%
    7d ago$-0.26-10.3%
    Current$-0.29
    Revenue Consensus
    $49M
    Range$42M - $55M
    6 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.92 - $0.25
    6 analysts
    EPS RevisionsNo revisions (7d)
    4
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.26-2.4%
    60d ago$-0.16-70.6%
    30d ago$-0.23-16.1%
    7d ago$-0.23-16.1%
    Current$-0.27
    Revenue Consensus
    $59M
    Range$51M - $70M
    6 analysts
    Last 12 of 38 reported quarters and 3 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.90$0.22 - $2.44--6--
    Sep 26EST
    		-$-0.27$-0.92 - $0.25--6
    4
    1
    30d
    		-
    Jun 26EST
    		-$-0.29$-0.43 - $-0.02--6
    4
    2
    30d
    		-
    Apr 26
    Reported May 15
    		$-0.43$-0.38$-0.38 - $-0.38-14.27%Miss1
    0
    1
    30d
    		+56.6%
    Jan 26
    Reported Mar 24
    		$0.94$-0.53$-0.53 - $-0.53+277.36%Beat1
    2
    3
    30d
    		+202.2%
    Oct 25
    Reported Nov 10
    		$-0.92$-0.91$-0.91 - $-0.91-1.10%Miss1
    1
    5
    30d
    		-1.1%
    Jul 25
    Reported Sep 11
    		$-1.12$-0.90$-1.28 - $-0.72-24.44%Miss7
    1
    3
    30d
    		-28.7%
    Apr 25
    Reported Jul 10
    		$-0.99$-0.81$-0.95 - $-0.73-22.22%Miss8
    7
    1
    30d
    		+2.9%
    Jan 25
    Reported Mar 12
    		$-0.92$-0.87$-0.98 - $-0.78-5.75%Miss9
    0
    5
    30d
    		-9.5%
    Oct 24
    Reported Dec 5
    		$-0.91$-0.91$-0.94 - $-0.85+0.00%Beat5
    1
    2
    30d
    		-13.7%
    Jul 24
    Reported Sep 5
    		$-0.87$-0.94$-1.02 - $-0.80+7.45%Beat5
    0
    1
    30d
    		-17.6%
    Apr 24
    Reported Jul 11
    		$-1.02$-0.73$-0.84 - $-0.55-39.73%Miss6
    No revisions (30d)
    		-32.5%
    Jan 24
    Reported Mar 11
    		$-0.84$-0.80$-0.87 - $-0.69-5.00%Miss6
    2
    0
    30d
    		-12.0%
    Oct 23
    Reported Dec 7
    		$-0.80$-0.78$-0.92 - $-0.66-2.56%Miss5
    No revisions (30d)
    		+11.1%
    Jul 23
    Reported Sep 7
    		$-0.74$-0.84$-0.93 - $-0.73+11.90%Beat5
    No revisions (30d)
    		+21.3%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.97
    SMA 20$26.88
    SMA 50$24.29
    SMA 200$16.98
    EMA 10$26.95
    EMA 20$26.60
    EMA 50$24.46
    EMA 200$18.63

    MACD

    Line: 0.68Signal: 0.90Hist: -0.21

    ADX

    ADX: 57.6+DI: 40.5-DI: 9.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$26.06

    Bollinger Bands

    Upper Band$27.08
    Lower Band$26.68
    %B Position148%(Upper)
    Band Width0.80

    RSI (14-Day)

    Overbought
    75.9

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D99.5
    Williams %RN/A
    ROC (10d)0.5%
    Momentum0.13
    CCI (20d)87.8
    MFI (14d)80.0

    Volatility Measures

    ATR (14d)$0.20(0.7%)
    StdDev (20d)0.10
    Hist Vol1.9%(Low)

    Volume Flow

    VWAP$27.00
    OBV111.4M
    AD Line-62.5M
    CMF (20d)0.039

    Volume Metrics

    Avg Vol (20d)3.1M
    Vol RatioN/A
    VWMA (20d)$26.84

    Pivot Points

    R3$27.00
    R2$27.00
    R1$27.00
    Pivot Point$27.00
    S1$27.00
    S2$27.00
    S3$27.00

    Advanced Oscillators

    TSI51.12
    Ultimate Osc65.4
    KST131.07

    Financial Data

    QuarterApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Total Revenue$59.92M$40.86M$40.86M$1.43M$0$0$0$0$1.21M$0$0$0
    Cost of Revenue$3.98M$3.09M$3.44M$590,000$15.89MN/AN/A$224,000$25.25M$207,000$19.09M$19.31M
    Gross Profit$55.95M$37.77M$37.42M$836,000$-15,891,000N/AN/A$-224,000$-25,248,000$-207,000$-19,089,000$-19,307,000
    Operating Expenses$67.46M$64.31M$60.86M$59.84M$39.14M$42.94M$45.81M$44.22M$23.21M$32.94M$10.66M$9.79M
    R&D$8.85M$12.42M$12.42M$15.16M$15.89M$12.59M$16.61M$26.61M$25.25M$22.52M$19.09M$19.31M
    SG&A$0$48.80M$46.52M$44.68M$39.14M$30.35M$29.20M$17.60M$23.21M$10.63M$10.66M$9.79M
    Operating Income$-11,511,500$-23,442,000$-23,442,000$-59,009,000$-55,030,000$-42,940,000$-45,811,000$-44,215,000$-48,455,000$-33,151,000$-29,746,000$-29,093,000
    Interest Income$0$2.55M$0$1.85M$1.99M$1.39M$1.36M$1.69M$1.51M$684,000$776,000$923,000
    Interest Expense$8.65M$5.59M$5.59M$3.52M$2.94M$2.84M$0$0$0$0$0$0
    Income Before Tax$-12,470,500$-23,487,000$-23,487,000$-57,939,000$-53,081,000$-44,262,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    Income Tax Expense$-7,098,500$0$2.16M$2.16M$-855,000$4.25M$0$0$856,000$0$523,000$-1,379,000
    Net Income$-5,372,000$-23,487,000$-23,487,000$-60,096,000$-52,226,000$-48,509,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    EBITDA$-3,236,500N/A$-17,546,000$-54,165,000$-49,877,000$-41,191,000$-42,041,000$-40,219,000$-44,430,000$-28,821,000$-27,453,000$-25,124,000
    EBIT$-3,823,000N/A$-17,901,000$-54,417,000$-50,138,000$-41,420,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KALV

    News

    KalVista Pharmaceuticals stock holds at $15.20 as investors await data

    KalVista Pharmaceuticals stock closed at $15.20 on September 22, 2026, with a market capitalization of $420 million. The company reported $38.6 million in Q2 fiscal 2026 revenue, alongside a net loss of $24.8 million...

    AD HOC NEWS•9/22/26•Neutral

    KalVista Pharmaceuticals (KALV): Venrock group now reports 0% ownership stake

    Venrock-affiliated entities and individuals, including Nimish Shah and Bong Y. Koh, have filed an amended Schedule 13G/A for KalVista Pharmaceuticals (KALV), reporting a 0% beneficial ownership stake as of June 30...

    Stock Titan•8/14/26•Neutral

    Tang Capital exits KalVista Pharmaceuticals (KALV) reporting 0% beneficial ownership

    Tang Capital entities, including Tang Capital Management, LLC and Kevin Tang, have filed an amended Schedule 13G/A...

    Stock Titan•8/14/26•Somewhat-Bearish

    KalVista Pharmaceuticals (KALV) investor SilverArc now reports 0% ownership stake

    SilverArc Capital Management, LLC and Devesh Gandhi have filed an amended Schedule 13G/A, disclosing that they no longer beneficially own any shares of KalVista Pharmaceuticals, Inc. (KALV). They now report 0 shares...

    Stock Titan•8/14/26•Neutral

    KalVista Pharmaceuticals (NASDAQ: KALV) investor reports 0% ownership in Class A stock

    SilverArc Capital Management, LLC and Devesh Gandhi have reported a 0% beneficial ownership in KalVista Pharmaceuticals, Inc.'s Class A Common Stock...

    Stock Titan•8/11/26•Neutral

    KALV Competitors

    CompanyTicker
    Cronos Group IncCRON
    Structure Therapeutics Inc. American Depositary SharesGPCR
    Innoviva IncINVA
    Eton Pharmaceuticals IncETON
    Pennant Group IncPNTG
    Mineralys Therapeutics, Inc. Common StockMLYS
    Nutex Health IncNUTX
    STAAR Surgical CompanySTAA

    Sector: Healthcare

    KALV Bull Case vs Bear Case

    Bear case

    • KALV beat EPS estimates in 25.0% of its last 8 reported quarters.

    KALV Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    27.1%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $-0.29
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    4 up, 2 down

    KALV Earnings Call

    The latest KALV earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    KALV ETF Holders

    GNG tracks 5 ETFs that hold KALV. The largest weights:

    1. BlackRock Health Sciences Trust (BME), 0.07% of the fund
    2. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    3. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.02% of the fund
    4. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    5. Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
    Open the ETF Stock Exposure tool for KALV

    See insider activity

    Frequently Asked Questions About KALV

    Does KALV pay dividends?

    Kalvista Pharmaceuticals Inc (KALV) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In